Conventional Chondrosarcoma, Dedifferentiated Chondrosarcoma, Mesenchymal Chondrosarcoma, Myxoid Liposarcoma
Conditions
Brief summary
Chondrosarcoma and liposarcoma consists of different subtypes with a wide range of patient survival. Current treatment options consist of wide surgical resection, however for patients with a local recurrence or metastatic disease the outcome is poor. New treatment options being evaluated and mouse models show in vivo that mammilian target of rapamycin (mTOR) inhibition can prevent tumour growth. mTOR is an kinase that is present in two complexes and thereby activates multiple pathways. Aberrant mTOR signalling is known to be involved in cancer cell survival. Several clinical studies for patients with bone or soft tissue sarcoma treated with mTOR inhibitors have been conducted and they show promising results. From these studies the investigators can conclude that the combination of an mTOR inhibitor with cyclophosphamide shows promising results in chondrosarcoma. With the lack of other treatment options for unresectable and metastatic chondrosarcoma or myxoid liposarcoma the Eurosarc consortium (www.eurosarc.eu) decided to treat these patients in a standardised way according to a common protocol with the combination of sirolimus and cyclophosphamide using the growth modulation index for evaluation in the current clinical study protocol.
Interventions
DRUGsirolimus and cyclophosphamide
Sponsors
Leiden University Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Pathologically proven conventional chondrosarcoma * Or pathologically proven myxoid liposarcoma with PIK3CA mutation or Phosphatase and tensin homolog (PTEN) loss * Or pathologically proven mesenchymal or dedifferentiated chondrosarcoma * Patient is 18 years and up * Documented radiographic progression of disease according to RECIST 1.1 criteria in last 6 months * Written signed informed consent * Adequate bone marrow function (Hb ≥ 6.0 mmol/L, absolute neutrophil count ≥ 1.5 x 109/L, platelets ≥ 80 x 109/L) * Availability of archival tumor material for central review or be able to perform a 3 core fresh biopsy * Ability to adhere to the study visits and all protocol requirements
Exclusion criteria
* Previously treated with an mTOR inhibitor * Known to be allergic to cyclophosphamide * Life expectancy of less than 3 months * No measurable lesions according to RECIST 1.1 * Eastern cooperative oncology group (ECOG) Performance status \>2 * Major surgery less than 4 weeks prior to start of treatment * Known human immunodeficiency virus (HIV) positivity * A decreased renal function with calculated glomerular filtration rate (GFR) \< 30ml/min * Systemic anti-cancer therapy within 28 days prior to the first dose of study drug , or radiotherapy to a target lesion within 21 days prior to the first dose of study drug * Pregnant or lactating women * Other invasive malignancies diagnosed within the last 5 years, except non-melanoma skin cancer and localised cured prostate and cervical cancer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The time to progression after start of treatment combination treatment of sirolimus and cyclophosphamide | 16 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Comparing pre-treatment tumor material and tumor material taken during treatment using immunohistochemistry to compare activation of the pS6, Bcl-2 and mTor pathway and DNA analysis for taqman analysis to search for hotspot mutations. | 8 weeks | — |
| Register adverse events to evaluate the patient safety and tolerability of the sirolimus and cyclophosphamide combination in myxoid liposarcoma and chondrosarcoma | every 8 weeks until progression (average of 1 year) | — |
| To evaluate the response according to response evaluation criteria in solid tumors (RECIST) 1.1 | every 8 weeks until progression (average of 1 year) | — |
| Using the growth modulation index (GMI) to evaluate treatment efficiency | every 8 weeks until progression (average of 1 year) | GMI: Time to progression during sirolimus/cyclophosphamide treatment (TTP2) divided by time to progression before start of this treatment TTP1 |
| The overall survival after start of treatment till death | every 8 weeks until progression (average of 1 year) | — |
Countries
Netherlands, Spain
Outcome results
None listed